Monte Rosa posts Q4 net loss $46.1M; cash runway into 2029; positive Phase 1 data for NEK7 degrader MRT-8102

Monte Rosa Therapeutics, Inc.

Q4 net loss $46.1M vs $13.4M in Q4 2024; full-year net loss decreased to $38.6M from $72.7M.
Cash, equivalents, securities $382.1M at Dec 31, 2025; $345M Jan 2026 offering extends runway into 2029.
Interim Phase 1 data for NEK7 degrader MRT-8102: 85% CRP reduction in elevated CVD-risk subjects; unblinded safety shows no SAEs.
Plans to initiate multiple Phase 2 studies of MRT-8102 in H2 2026 (ASCVD, gout, hidradenitis suppurativa).
MRT-2359 in mCRPC with AR mutations: 100% PSA response rate; Phase 2 with apalutamide planned Q3 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Monte Rosa Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.

Period: the fourth quarter and full year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 17, 2026, Monte Rosa Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended December 31, 2025.

View on SEC.gov

Browse all earnings releases →

Monte Rosa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-109353

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.